SCHEMBL1035376

SCHEMBL1035376

O=C(Nc1cccnc1)c1cc(F)cc2ccc(-c3cccc(C(F)(F)F)c3)nc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.52
KIT P10721 1/20 0.52
KDR P35968 1/20 0.52
MAPK14 Q16539 1/20 0.52
BRAF P15056 1/20 0.52
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
TSHR P16473 1/20 0.51
MAPT P10636 2/20 0.50
LRRK2 Q5S007 2/20 0.49
SRPK3 Q9UPE1 1/20 0.49
RXFP1 Q9HBX9 1/20 0.48
PIKFYVE Q9Y2I7 2/20 0.47
CYP11B1 P15538 1/20 0.47
CYP11B2 P19099 1/20 0.47
LMNA P02545 1/20 0.47
XBP1 P17861 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1032356 0.90 CSF1R (0.54) CSF1RKITKDRMAPK14BRAF
SCHEMBL1033582 0.85 CSF1R (0.51) CSF1RKITKDRMAPK14BRAF
SCHEMBL1034424 0.81 CSF1R (0.52) CSF1RKITKDRMAPK14BRAF
SCHEMBL1034553 0.80 EPHX2 (0.54) CSF1RKITKDRMAPK14BRAF
SCHEMBL1031208 0.80 SCN9A (0.48) KDRKMT2AMEN1MAPTLMNA
SCHEMBL1032240 0.79 KMO (0.55) KMT2AMEN1SMN1; SMN2
SCHEMBL1034072 0.79 JAK2 (0.51) CSF1RKITKDRMAPTRXFP1
SCHEMBL1034065 0.79 RXFP1 (0.53) KMT2AMEN1MAPTRXFP1LMNA
SCHEMBL17772348 0.78 CYP11B2 (0.48) CSF1RKITKDRMAPK14BRAF
SCHEMBL1031934 0.78 EGLN1 (0.60) KMT2AMEN1TSHRMAPTCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
EP-2273992-B1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-05-25 EP disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-02-24 US disclosed
EP-2273992-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134973-A1 QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046110-A1 QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 CSF1R 995/4885KIT 2952/4885KDR 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.